NetworkNewsBreaks – Rosetta Genomics (NASDAQ: ROSG) Receives Two U.S. Patent Allowances for RosettaGx Reveal™ microRNAs

Rosetta Genomics (NASDAQ: ROSG) shares are nudging higher after the company said the U.S. Patents and Trademark Office has granted two patent allowances for divisional patents of the parent application titled “microRNAs and uses thereof.” The company said the patents are important markers for its RosettaGX Reveal™ thyroid cancer assay, as this strengthens its intellectual property portfolio and provides opportunities for monetization. “We are creating a strong intellectual property position in microRNAs and thyroid cancer diagnostics. Of note, there are approximately 500 peer-reviewed publications that confirm the effectiveness of microRNAs as biomarkers in the diagnosis of thyroid cancer which makes these and other microRNAs in our RosettaGX Reveal™ assay potentially even more valuable. We believe there may be opportunities to monetize this and other intellectual property pursuant to outlicenses to others working in this field. We are pursuing additional patents for our Reveal assay and look forward to their issuance. Our solid patent position, along with Reveal’s numerous competitive advantages including the ability to work off of routinely prepared FNA smears, creates the opportunity for significant revenue growth this year and well into the future,” Rosetta president and CEO Kenneth A. Berlin stated in the news release.

To view the full press release, visit: http://nnw.fm/C6JmQ

About Rosetta Genomics

Rosetta offers rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of unique diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of cancer in thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. To learn more, visit www.rosettagx.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s